Streetbeat News

Earnings

AEMD

Aethlon Medical shares are trading lower following worse-than-expected Q1 EPS results.

Portfolio Pulse from Benzinga Newsdesk

August 14, 2024 | 8:53 pm

NRXP

NRX Pharmaceuticals (NASDAQ:NRXP) reported a Q2 2024 GAAP EPS of $(0.75), missing the analyst consensus estimate of $(0.58) by 29.31%. However, this is an improvement from the $(1.21) per share loss in the same period last year.

Portfolio Pulse from Benzinga Newsdesk

August 14, 2024 | 8:53 pm

ARDT

Ardent Health has announced its financial expectations for FY24, projecting total revenue between $5.75 billion and $5.90 billion and earnings per share (EPS) between $1.23 and $1.37.

Portfolio Pulse from Benzinga Newsdesk

August 14, 2024 | 8:52 pm

SQFT

Presidio Property Trust (NASDAQ:SQFT) reported a Q2 FFO loss of $(0.04) per share, a significant decrease from $(0.02) per share YoY. Sales increased slightly to $4.59M from $4.54M YoY.

Portfolio Pulse from Benzinga Newsdesk

August 14, 2024 | 8:52 pm

BENF

Beneficient shares are trading higher after the company reported a year-over-year increase in Q1 revenue results.

Portfolio Pulse from Benzinga Newsdesk

August 14, 2024 | 8:52 pm

GPRK

GeoPark has maintained its FY24 EBITDA guidance in the range of $420 million to $550 million.

Portfolio Pulse from Benzinga Newsdesk

August 14, 2024 | 8:51 pm

FIHL

Fidelis Insurance shares are trading lower after the company reported worse-than-expected Q2 financial results.

Portfolio Pulse from Benzinga Newsdesk

August 14, 2024 | 8:51 pm

GPRK

GeoPark (NYSE:GPRK) reported Q2 2024 earnings per share of $0.48, missing the analyst consensus estimate of $0.70 by 31.43%. The company also reported sales of $190.20 million, which missed the estimate of $194.50 million by 2.21%. Despite the misses, sales increased by 4.33% compared to the same period last year.

Portfolio Pulse from Benzinga Newsdesk

August 14, 2024 | 8:50 pm

ZOM

Zomedica (AMEX:ZOM) reported Q2 EPS of $(0.01), unchanged from last year, and sales of $6.13M, missing the $6.26M estimate. Sales increased by 1.84% YoY.

Portfolio Pulse from totan@benzinga.com

August 14, 2024 | 8:50 pm

ENSC

Ensysce Biosciences (NASDAQ:ENSC) reported Q2 EPS of $(0.22), beating the $(0.39) estimate, but missed sales estimates with $181.80K against the expected $300.00K. EPS improved by 77.55% YoY, while sales decreased by 62.93% YoY.

Portfolio Pulse from Benzinga Newsdesk

August 14, 2024 | 8:49 pm